 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH, a leading precision oncology company, is joining forces with leading patient advocacy groups to expand the Clear Your View initiative to raise awareness of the important role complete biomarker testing plays in guiding initial treatment decisions for newly diagnosed advanced colorectal cancer CRC patients. Current medical guidelines call for testing all six biomarkers in advanced CRC before starting treatment,2 yet mor 